ClinicalTrials.gg

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 421 studies for Precursor T-Cell Lymphoblastic Leukemia-Lymphoma across more than 10 countries. 75 are recruiting or about to start. 101 of them are mainly about Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

Status

Completed
209
Terminated
58
Recruiting
58
Status unknown
32
Withdrawn
24
Active, not recruiting
18

Phase

Phase 1
215
Phase 2
161
Phase 3
32
Early Phase 1
9
Phase 4
2

Where

United States
286
China
51
Italy
27
France
23
Germany
23
Canada
15

Who develops what

Add Precursor T-Cell Lymphoblastic Leukemia-Lymphoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 12 programs from 5 companies, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Beijing Biotech, Chongqing Precision Biotech and PersonGen BioTherapeutics (Suzhou) here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DexamethasoneEarlier only
Evidence
  • NCT02999633 · Sanofi · Phase 2 · background · “dexamethasone” · registered Dec 2016
  • NCT02518113 · Eli Lilly and Company · Phase 2 · background · “Dexamethasone” · registered Aug 2015
  • NCT01626664 · Kyowa Kirin Co., Ltd. · Phase 2 · comparator · “DHAP” · registered Jun 2012
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 14 Mar 2027 est.Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module, Autologous BCMA/CD38 dual-target CAR-T module, Autologous BCMA/GPRC5D dual-target CAR-T, Autologous CD33/CD123 dual-target CAR-T module, Autologous CD33/CLL1 dual-target CAR-T module, Autologous CD5/CD7 dual-target CAR-T module · Beijing Biotech · Phase 2 registry mapping onlyNCT07523555 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies — primary endpoint: Incidence of dose-limiting toxicities (DLTs) by module and dose level · 96 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 15 open · Alkylating agents 7 open · Corticosteroids 5 open · Tyrosine kinase inhibitors (TKIs) 5 open · Proteasome inhibitors 3 open

Coming up

22studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger. 35 (60%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (2%) take healthy volunteers.

Recruiting studies that take each age, of 58
AgeWomenMen
1029 (50%)29 (50%)
1856 (97%)56 (97%)
3047 (81%)47 (81%)
4044 (76%)44 (76%)
5043 (74%)43 (74%)
6542 (72%)42 (72%)
7534 (59%)34 (59%)
8528 (48%)28 (48%)

Across all 421 studies, recruiting or not: 34% stop at 75 or younger and 19% at 65; 38% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies take

Of 43 phase 2 interventional studies under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 63 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 156 mo39–76 · 42 studies——
Phase 263 mo39–81 · 43 studies—64 mo43–97 · 40 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 421. Browse all 421 → or search them.